DS
DSKYF.US Daiichi Sankyo Company Limited
- Market cap
- USD 32.9B
- P/E
- 18.6x
- P/B
- 2.98x
- ROE
- 17.4%
- Dividend yield
- 3.46%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is DSKYF.US undervalued?
Graham numberDSKYF.US trades 57.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Daiichi Sankyo Company Limited fundamental analysis
No fundamental analysis for Daiichi Sankyo Company Limited yet.
Daiichi Sankyo Company Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Daiichi Sankyo Company Limited
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanfly…
Full company profileDaiichi Sankyo Company Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Daiichi Sankyo Company Limited annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 955B | 960B | 930B | 982B | 963B | 1.04T | 1.28T | 1.60T | 1.89T | 2.14T | 2.34T |
| Gross Profit | 606B | 614B | 565B | 639B | 624B | 682B | 915B | 1.19T | 1.47T | 1.46T | 1.85T |
| Operating Income | 128B | 112B | 90.5B | 118B | 63.8B | 73.0B | 121B | 212B | 332B | 209B | 388B |
| EBITDA | 143B | 132B | 138B | 171B | 134B | 131B | 170B | 271B | 436B | 287B | 475B |
| Net Income | 53.5B | 60.3B | 93.4B | 129B | 76.0B | 67.0B | 109B | 201B | 296B | 262B | 307B |
| EPS | 26 | 30 | 48 | 66 | 39 | 35 | 57 | 105 | 156 | 141 | 165 |
| Balance Sheet | |||||||||||
| Total Assets | 1.91T | 1.90T | 2.09T | 2.11T | 2.09T | 2.22T | 2.51T | 3.46T | 3.46T | 4.03T | 4.28T |
| Total Liabilities | 744B | 765B | 838B | 792B | 807B | 865B | 1.06T | 1.77T | 1.83T | 2.36T | 2.49T |
| Shareholders' Equity | 1.18T | 1.13T | 1.25T | 1.31T | 1.27T | 1.35T | 1.45T | 1.69T | 1.62T | 1.67T | 1.77T |
| Cash & Short-term Investments | 798B | 594B | 560B | 520B | 825B | 844B | 608B | 1.22T | 721B | 453B | 684B |
| Total Debt | 282B | 282B | 262B | 224B | 184B | 214B | 193B | 102B | 101B | 302B | 503B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 136B | 108B | 92.0B | 197B | 192B | 139B | 115B | 599B | 53.8B | 78.1B | 102B |
| Capital Expenditure | 53.0B | 38.0B | 66.6B | 52.6B | 64.1B | 76.7B | 67.4B | 123B | 188B | 129B | 135B |
| Free Cash Flow | 83.3B | 70.4B | 25.4B | 144B | 128B | 62.5B | 47.1B | 476B | -134B | -51.0B | -33.0B |
| Ratios | |||||||||||
| ROE | 4.5% | 5.3% | 7.5% | 9.9% | 6.0% | 5.0% | 7.6% | 11.9% | 18.2% | 15.6% | 17.4% |
| ROA | 2.8% | 3.2% | 4.5% | 6.1% | 3.6% | 3.0% | 4.4% | 5.8% | 8.6% | 6.5% | 7.2% |
| Net Profit Margin | 5.6% | 6.3% | 10.0% | 13.1% | 7.9% | 6.4% | 8.5% | 12.5% | 15.7% | 12.2% | 13.1% |
| Debt to Equity | 0.24x | 0.25x | 0.21x | 0.17x | 0.14x | 0.16x | 0.13x | 0.06x | 0.06x | 0.18x | 0.28x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Daiichi Sankyo Company Limited dividends
- Dividend yield
- 3.46%
- Forward dividend
- 0.63 USD
- Payout ratio
- 49.4%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 129B | 70 | 49.4% |
| 2025 | JPY 114B | 60 | 38.7% |
| 2024 | JPY 67.1B | 35 | 33.4% |
| 2023 | JPY 54.6B | 28 | 50.0% |
| 2022 | JPY 51.7B | 27 | 77.2% |
| 2021 | JPY 48.9B | 25 | 64.4% |
| 2020 | JPY 45.4B | 23 | 35.1% |
| 2019 | JPY 45.3B | 23 | 48.5% |
| 2018 | JPY 46.4B | 23 | 77.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:1 on Sep 29, 2020.
Who owns Daiichi Sankyo Company Limited
- Insiders 0.17%
- Institutions 58.04%
- Public & others 41.79%
- Shares outstanding 1.82B
- Free float 1.82B
Daiichi Sankyo Company Limited company profile
- Company name
- Daiichi Sankyo Company Limited
- Ticker
- DSKYF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 20,171
- Fiscal year end
- March
- Address
- Daiichi Sankyo Building A/B, Chuo, Japan, 103-8426
- Phone
- 81 3 6225 1111
- Website
- daiichisankyo.com
About Daiichi Sankyo Company Limited
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer for the treatment of iron deficiency anemia; Vimpat, an anti-seizure medication; and Reyvow for the treatment of acute migraine attacks. Further, it provides Daichirona, a coronavirus RNA vaccine; Flumist, an intranasal live attenuated influenza vaccine; adsorbed cell culture-derived influenza vaccine; measles rubella combined vaccine; and mump vaccine. The company was formerly known as Sankyo Co. Ltd. and changed its name to Daiichi Sankyo Company, Limited in September 2005. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.
Daiichi Sankyo Company Limited management
10- Mr. Hiroyuki OkuzawaPresident, CEO & Representative Director · born 1962
- Mr. Takashi MatsumotoSr. Exec Ofcr, Chief Corp Affairs Ofcr, Head of Global Corp Affairs & HR, CHRO & Director · born 1964
- Mr. Joseph Kenneth KellerHead of Oncology Business Unit & Global Oncology Business and Director · born 1963
- Mr. Tomohiro KodamaSenior Executive Officer, Head of Global Corporate Planning & Management and CFO
- Tetsuya OhiraCorporate Officer, Head of Business Transformation & CTO
- Naoto TsukaguchiSenior Executive Officer, Head of Global Legal & IP, GC
- Matt AllegrucciHead of Global Compliance & Risk Management and Chief Compliance Officer
- Mr. Joji NakayamaSenior Adviser · born 1950
- Mr. Stuart Mackey J.D.Global Head of Business Development & Director
- Thierry GrusonHead of Global Oncology Marketing